What happens to the Astrazeneca anti Covid vaccine
Astrazeneca has announced that it has resumed clinical trials on the Covid-19 vaccine in Great Britain. "" The anomalous case found was not related to the vaccine, "according to Minister Speranza. All the details
Astrazeneca has announced that it has resumed clinical trials on the Covid-19 vaccine in Great Britain which had been stopped after a volunteer had an adverse reaction ( here the insight from Start Magazine ). The pharmaceutical giant explained that it had been authorized to resume the trial by all the British regulatory bodies.
THE WORDS OF MINISTER SPERANZA
"The anomalous case found was not related to the vaccine", the Minister of Health, Roberto Speranza, said in an interview with Repubblica: "As the European Union we are buying a 6 + 1 package, the AstraZeneca package is one of the six and is later stage. There are others too though. And innovative treatments are about to arrive: in Siena Professor Rino Rappuoli is doing an extraordinary job on monoclonal antibodies from which effective drugs will come out ”.
THE ASTRAZENECA VACCINE
The Covid-19 vaccine at which the University of Oxford and AstraZeneca work is considered among the most promising in the world: cynical tests will resume after the brief interruption announced Thursday and due – at least according to rumors – to inflammation of the spinal cord of one of the volunteers ( here the in-depth analysis of Start Magazine ).
THE EXPLANATIONS OF THE UNIVERSITY OF OXFORD
Speaking of the resumption of tests in which 18,000 volunteers are currently participating, the university explained that, in such extensive tests, it is to be expected that some participants will have a so-called "adverse reaction": "Each case must be carefully evaluated" and the university has not specified any date of resumption of the trials.
THE FINAL PHASE
Developed in record time (this type of research usually takes years), the vaccine is in the final stage of clinical trials and is being tested in Great Britain, the United States, Brazil and South Africa.
THE PUBLICATION ON LANCET
According to the results of the first trials, published last July in the British medical journal The Lancet , it is safe and "trains" the immune system, providing double protection, since it would develop the production of antibodies and also of white blood cells or "cell-type lymphocytes." T ".
THE GEOPOLITICS OF THE VACCINE
In the world there are more than 30 vaccines that are being tested on humans in various countries around the world to contain a pandemic that is bringing the economies of the planet to their knees and which has already caused over 28 million cases and more than 900,000 deaths. And nine of these vaccines are in the final stages.
THE PURCHASES OF EUROPE
At the end of August, the EU closed a "first contract" with Astrazeneca which guarantees the 27 member countries access to 300 million doses: the contract was signed on behalf of all member states and the vaccine will be distributed proportionately in based on the population of each country.
DI LORENZO SAFETY DEVICES (IRBM)
"The fact that the independent scientific committee ruled within 24 hours means that it was clear and certain that there is no connection between the Oxford-Astrazeneca vaccine candidate and the suspicious reaction that occurred in a volunteer" among the 50,000 who are testing the drug. This was stated by the president of Irbm Di Pomezia, who collaborated in the development of the vaccine candidate, Piero di Lorenzo ( who on TV put forward two hypotheses on the reasons for the temporary stop from testing ).
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/innovazione/che-cosa-succede-al-vaccino-astrazeneca-anti-covid/ on Sun, 13 Sep 2020 09:30:57 +0000.